Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB T2N 2T9, Canada.
Toxins (Basel). 2020 Dec 17;12(12):803. doi: 10.3390/toxins12120803.
Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade and has become established as a well-tolerated option for the preventive therapy of chronic migraine. Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of action is quite different from that of the new monoclonal antibodies directed against calcitonin gene-related peptide (CGRP) or its receptor, it is unlikely to be displaced to any major extent by them. Both will likely remain as important tools for patients with chronic migraine and the clinicians assisting them. New types of botulinum toxin selective for sensory pain neurons may well be discovered or produced by recombinant DNA techniques in the coming decade, and this may greatly enhance its therapeutic usefulness. This review summarizes the evolution of botulinum toxin use in headache management over the past several decades and its role in the preventive treatment of chronic migraine and other headache disorders.
A型肉毒毒素用于治疗慢性偏头痛已有十余年,已被确立为慢性偏头痛预防性治疗的一种耐受良好的选择。正在进行的研究逐渐揭示了其在偏头痛预防中的作用机制。鉴于其作用机制与针对降钙素基因相关肽(CGRP)或其受体的新型单克隆抗体有很大不同,因此不太可能被它们替代。两者都可能仍然是慢性偏头痛患者及其辅助治疗的临床医生的重要工具。未来十年,通过重组 DNA 技术可能会发现或生产出对感觉疼痛神经元具有选择性的新型肉毒毒素,这可能会极大地增强其治疗效果。这篇综述总结了过去几十年中肉毒毒素在头痛管理中的应用及其在慢性偏头痛和其他头痛疾病的预防性治疗中的作用的演变。